SOLO-2 (ENGOT-GCIG/AstraZeneca)
Trial Description:
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenence Monotherapy in Platinum Sensitive relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Lead Cooperative Group:
Trial Number:
Disease Site:
Recurrent Ovarian
Trial Status:
Completed
Contact person:
bvotan